Specifically, PDOs have lower levels of several factors (including B-cell lymphoma 2/Bcl-2, MMP2, Cathepsin D and Survivin) as compared to CTCDOs, suggesting that proteins related to tumor cell survival and aggressiveness increase during sequential stages of the disease. The gene discussed is BCL2; the disease is neoplasm.